conducted a meta-analysis (49) to assess the immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer, study showed only a 4% probability of serious adverse events. Here, PDCD1 is linked to non-small cell lung carcinoma.